nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—Tamibarotene—RARB—cervical cancer	0.0996	1	CrCbGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—RARB—cervical cancer	0.0325	0.0865	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—RARB—cervical cancer	0.0306	0.0813	CbGpPWpGaD
Bexarotene—RXRG—Retinoic acid receptors-mediated signaling—RARB—cervical cancer	0.029	0.0771	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—RARB—cervical cancer	0.0273	0.0725	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—RARB—cervical cancer	0.024	0.0638	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—RARB—cervical cancer	0.0226	0.06	CbGpPWpGaD
Bexarotene—RXRG—Vitamin A and Carotenoid Metabolism—RARB—cervical cancer	0.0218	0.0578	CbGpPWpGaD
Bexarotene—Febrile neutropenia—Topotecan—cervical cancer	0.0215	0.0435	CcSEcCtD
Bexarotene—Pelvic pain—Topotecan—cervical cancer	0.0212	0.043	CcSEcCtD
Bexarotene—RXRB—Vitamin A and Carotenoid Metabolism—RARB—cervical cancer	0.0205	0.0543	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.019	0.0504	CbGpPWpGaD
Bexarotene—Lung disorder—Topotecan—cervical cancer	0.0182	0.0369	CcSEcCtD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.0178	0.0474	CbGpPWpGaD
Bexarotene—Pleural effusion—Topotecan—cervical cancer	0.0169	0.0341	CcSEcCtD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—RARB—cervical cancer	0.0159	0.0424	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—RARB—cervical cancer	0.0142	0.0378	CbGpPWpGaD
Bexarotene—Hyperbilirubinaemia—Topotecan—cervical cancer	0.0142	0.0287	CcSEcCtD
Bexarotene—Bone pain—Topotecan—cervical cancer	0.0135	0.0273	CcSEcCtD
Bexarotene—Colitis—Topotecan—cervical cancer	0.0124	0.0251	CcSEcCtD
Bexarotene—Neuropathy—Topotecan—cervical cancer	0.0121	0.0245	CcSEcCtD
Bexarotene—RXRA—Nuclear Receptors—RARB—cervical cancer	0.0118	0.0313	CbGpPWpGaD
Bexarotene—Rash maculo-papular—Topotecan—cervical cancer	0.0117	0.0238	CcSEcCtD
Bexarotene—Neoplasm—Topotecan—cervical cancer	0.0117	0.0236	CcSEcCtD
Bexarotene—Sepsis—Topotecan—cervical cancer	0.0112	0.0227	CcSEcCtD
Bexarotene—Ear pain—Topotecan—cervical cancer	0.011	0.0222	CcSEcCtD
Bexarotene—RXRA—Vitamin A and Carotenoid Metabolism—RARB—cervical cancer	0.0107	0.0283	CbGpPWpGaD
Bexarotene—Dermatitis bullous—Topotecan—cervical cancer	0.00981	0.0199	CcSEcCtD
Bexarotene—Lethargy—Topotecan—cervical cancer	0.00957	0.0194	CcSEcCtD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—RARB—cervical cancer	0.0093	0.0247	CbGpPWpGaD
Bexarotene—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00844	0.0171	CcSEcCtD
Bexarotene—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00827	0.0167	CcSEcCtD
Bexarotene—Pancytopenia—Topotecan—cervical cancer	0.00769	0.0156	CcSEcCtD
Bexarotene—Neutropenia—Topotecan—cervical cancer	0.00758	0.0153	CcSEcCtD
Bexarotene—Weight increased—Topotecan—cervical cancer	0.00737	0.0149	CcSEcCtD
Bexarotene—Pneumonia—Topotecan—cervical cancer	0.00727	0.0147	CcSEcCtD
Bexarotene—Neuropathy peripheral—Topotecan—cervical cancer	0.00708	0.0143	CcSEcCtD
Bexarotene—Stomatitis—Topotecan—cervical cancer	0.00704	0.0143	CcSEcCtD
Bexarotene—Sweating—Topotecan—cervical cancer	0.00692	0.014	CcSEcCtD
Bexarotene—Epistaxis—Topotecan—cervical cancer	0.00681	0.0138	CcSEcCtD
Bexarotene—Haemoglobin—Topotecan—cervical cancer	0.00652	0.0132	CcSEcCtD
Bexarotene—Rhinitis—Topotecan—cervical cancer	0.0065	0.0132	CcSEcCtD
Bexarotene—Haemorrhage—Topotecan—cervical cancer	0.00648	0.0131	CcSEcCtD
Bexarotene—Hypoaesthesia—Topotecan—cervical cancer	0.00645	0.0131	CcSEcCtD
Bexarotene—Pharyngitis—Topotecan—cervical cancer	0.00644	0.013	CcSEcCtD
Bexarotene—RXRA—renal system—cervical cancer	0.00592	0.196	CbGeAlD
Bexarotene—Angiopathy—Topotecan—cervical cancer	0.00588	0.0119	CcSEcCtD
Bexarotene—Chills—Topotecan—cervical cancer	0.00582	0.0118	CcSEcCtD
Bexarotene—Alopecia—Topotecan—cervical cancer	0.00573	0.0116	CcSEcCtD
Bexarotene—Malnutrition—Topotecan—cervical cancer	0.00564	0.0114	CcSEcCtD
Bexarotene—Back pain—Topotecan—cervical cancer	0.00546	0.0111	CcSEcCtD
Bexarotene—Muscle spasms—Topotecan—cervical cancer	0.00543	0.011	CcSEcCtD
Bexarotene—Ill-defined disorder—Topotecan—cervical cancer	0.00524	0.0106	CcSEcCtD
Bexarotene—Anaemia—Topotecan—cervical cancer	0.00522	0.0106	CcSEcCtD
Bexarotene—Malaise—Topotecan—cervical cancer	0.00509	0.0103	CcSEcCtD
Bexarotene—Leukopenia—Topotecan—cervical cancer	0.00505	0.0102	CcSEcCtD
Bexarotene—RXRB—decidua—cervical cancer	0.00497	0.165	CbGeAlD
Bexarotene—Cough—Topotecan—cervical cancer	0.00493	0.00997	CcSEcCtD
Bexarotene—Myalgia—Topotecan—cervical cancer	0.00481	0.00973	CcSEcCtD
Bexarotene—Arthralgia—Topotecan—cervical cancer	0.00481	0.00973	CcSEcCtD
Bexarotene—Chest pain—Topotecan—cervical cancer	0.00481	0.00973	CcSEcCtD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.0048	0.0128	CbGpPWpGaD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00477	0.00966	CcSEcCtD
Bexarotene—Discomfort—Topotecan—cervical cancer	0.00475	0.00961	CcSEcCtD
Bexarotene—RXRA—female reproductive system—cervical cancer	0.00474	0.157	CbGeAlD
Bexarotene—Infection—Topotecan—cervical cancer	0.00458	0.00927	CcSEcCtD
Bexarotene—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—cervical cancer	0.00453	0.012	CbGpPWpGaD
Bexarotene—Nervous system disorder—Topotecan—cervical cancer	0.00452	0.00915	CcSEcCtD
Bexarotene—Thrombocytopenia—Topotecan—cervical cancer	0.00451	0.00913	CcSEcCtD
Bexarotene—Skin disorder—Topotecan—cervical cancer	0.00447	0.00906	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—INSM1—cervical cancer	0.00447	0.0119	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Topotecan—cervical cancer	0.00445	0.00902	CcSEcCtD
Bexarotene—Anorexia—Topotecan—cervical cancer	0.00439	0.00889	CcSEcCtD
Bexarotene—RXRA—female gonad—cervical cancer	0.00431	0.143	CbGeAlD
Bexarotene—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—cervical cancer	0.00426	0.0113	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Topotecan—cervical cancer	0.0042	0.0085	CcSEcCtD
Bexarotene—Paraesthesia—Topotecan—cervical cancer	0.00414	0.00838	CcSEcCtD
Bexarotene—Dyspnoea—Topotecan—cervical cancer	0.00411	0.00832	CcSEcCtD
Bexarotene—Dyspepsia—Topotecan—cervical cancer	0.00406	0.00821	CcSEcCtD
Bexarotene—Decreased appetite—Topotecan—cervical cancer	0.004	0.00811	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Topotecan—cervical cancer	0.00398	0.00805	CcSEcCtD
Bexarotene—Fatigue—Topotecan—cervical cancer	0.00397	0.00804	CcSEcCtD
Bexarotene—Constipation—Topotecan—cervical cancer	0.00394	0.00798	CcSEcCtD
Bexarotene—Pain—Topotecan—cervical cancer	0.00394	0.00798	CcSEcCtD
Bexarotene—Feeling abnormal—Topotecan—cervical cancer	0.0038	0.00769	CcSEcCtD
Bexarotene—Gastrointestinal pain—Topotecan—cervical cancer	0.00377	0.00763	CcSEcCtD
Bexarotene—Abdominal pain—Topotecan—cervical cancer	0.00364	0.00737	CcSEcCtD
Bexarotene—Body temperature increased—Topotecan—cervical cancer	0.00364	0.00737	CcSEcCtD
Bexarotene—RXRB—female gonad—cervical cancer	0.00356	0.118	CbGeAlD
Bexarotene—RXRB—vagina—cervical cancer	0.00354	0.117	CbGeAlD
Bexarotene—Hypersensitivity—Topotecan—cervical cancer	0.00339	0.00687	CcSEcCtD
Bexarotene—Asthenia—Topotecan—cervical cancer	0.00331	0.00669	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—RARB—cervical cancer	0.00328	0.00871	CbGpPWpGaD
Bexarotene—Pruritus—Topotecan—cervical cancer	0.00326	0.0066	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00323	0.00859	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.00317	0.00842	CbGpPWpGaD
Bexarotene—Diarrhoea—Topotecan—cervical cancer	0.00315	0.00638	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—RARB—cervical cancer	0.00308	0.00819	CbGpPWpGaD
Bexarotene—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.00305	0.00811	CbGpPWpGaD
Bexarotene—Dizziness—Topotecan—cervical cancer	0.00305	0.00617	CcSEcCtD
Bexarotene—Vomiting—Topotecan—cervical cancer	0.00293	0.00593	CcSEcCtD
Bexarotene—Rash—Topotecan—cervical cancer	0.0029	0.00588	CcSEcCtD
Bexarotene—Dermatitis—Topotecan—cervical cancer	0.0029	0.00588	CcSEcCtD
Bexarotene—Headache—Topotecan—cervical cancer	0.00289	0.00584	CcSEcCtD
Bexarotene—Nausea—Topotecan—cervical cancer	0.00274	0.00554	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—CTNNB1—cervical cancer	0.00245	0.0065	CbGpPWpGaD
Bexarotene—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—cervical cancer	0.00222	0.00589	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—NOTCH2—cervical cancer	0.00217	0.00577	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—STAT3—cervical cancer	0.00213	0.00566	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—NOTCH2—cervical cancer	0.00204	0.00543	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—RARB—cervical cancer	0.00161	0.00427	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—RARB—cervical cancer	0.00158	0.00419	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—RARB—cervical cancer	0.00148	0.00394	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—NOTCH1—cervical cancer	0.00134	0.00357	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—NOTCH1—cervical cancer	0.00126	0.00336	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.00121	0.00321	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—CTNNB1—cervical cancer	0.0012	0.00318	CbGpPWpGaD
Bexarotene—CYP2C9—female reproductive system—cervical cancer	0.00115	0.0381	CbGeAlD
Bexarotene—CYP3A4—renal system—cervical cancer	0.00109	0.0363	CbGeAlD
Bexarotene—RXRA—Generic Transcription Pathway—NOTCH2—cervical cancer	0.00106	0.00283	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NOTCH2—cervical cancer	0.00105	0.00278	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—STAT3—cervical cancer	0.00104	0.00278	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NOTCH2—cervical cancer	0.000983	0.00261	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000914	0.00243	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000881	0.00234	CbGpPWpGaD
Bexarotene—CYP3A4—female reproductive system—cervical cancer	0.000876	0.029	CbGeAlD
Bexarotene—RXRA—Developmental Biology—HES1—cervical cancer	0.000821	0.00218	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—RARB—cervical cancer	0.000773	0.00205	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CA9—cervical cancer	0.000707	0.00188	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000698	0.00185	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—NOTCH1—cervical cancer	0.000659	0.00175	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—NOTCH1—cervical cancer	0.000647	0.00172	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—NOTCH1—cervical cancer	0.00062	0.00165	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—NOTCH1—cervical cancer	0.000608	0.00162	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000586	0.00156	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NOTCH2—cervical cancer	0.000512	0.00136	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CTNNB1—cervical cancer	0.000412	0.00109	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—STAT3—cervical cancer	0.000359	0.000954	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—EGFR—cervical cancer	0.000326	0.000867	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—NOTCH1—cervical cancer	0.000317	0.000843	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—MTHFR—cervical cancer	0.000287	0.000763	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CA9—cervical cancer	0.000264	0.000702	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CA9—cervical cancer	0.000174	0.000463	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—MTHFR—cervical cancer	0.000107	0.000285	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MTHFR—cervical cancer	7.07e-05	0.000188	CbGpPWpGaD
